---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-26-000023"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:20:27.033484+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Halozyme full-year 2025 revenue $1.397B (up 38%), royalty record $868M; 2026 guidance reiterated

## Summary
- FY2025 total revenue $1.397B (+38% YoY); royalty revenue $868M (+52%) led by VYVGART Hytrulo, DARZALEX SC, Phesgo.
- GAAP net income $316.9M ($2.56 diluted EPS) includes $284.9M IPR&D charge for Surf Bio acquisition; adjusted EBITDA $657.6M.
- Q4 2025 revenue $451.8M (+52% YoY); net loss $141.6M due to Surf Bio charge; adjusted EBITDA $21.9M.
- 2026 guidance: total revenue $1.71–1.81B (growth 22–30%), royalty $1.13–1.17B, adjusted EBITDA $1.125–1.205B, non-GAAP EPS $7.75–8.25.
- Expanded delivery portfolio via Elektrofi and Surf Bio acquisitions; completed $1.5B convertible note offering.

## SEC filing metadata
- accession: 0001159036-26-000023
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000023/0001159036-26-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000023/halo-20260217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-26-000023
- JSON: https://secwatch.observer/filing/0001159036-26-000023.json
- Plain text: https://secwatch.observer/filing/0001159036-26-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.